Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression

Clinical trial NCT07001995 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07001995
Sponsor: Hunan Province Tumor Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Small Cell Lung Cancer Non Small Cell Lung Cancer Non Small Cell Lung Cancer NSCLC

Start date: 2026-05-01
Primary completion: 2027-12-30
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.